Dennis M. Lanfear
Net Worth

Last updated:

What is Dennis M. Lanfear net worth?

The estimated net worth of Mr. Dennis M. Lanfear is at least $36,142,207 as of 22 Nov 2023. He owns shares worth $782,912 as insider, has earned $17,159,295 from insider trading and has received compensation worth at least $18,200,000 in Coherus BioSciences, Inc..

What is the salary of Dennis M. Lanfear?

Mr. Dennis M. Lanfear salary is $1,820,000 per year as Chairman, Pres & Chief Executive Officer in Coherus BioSciences, Inc..

How old is Dennis M. Lanfear?

Mr. Dennis M. Lanfear is 70 years old, born in 1955.

What stocks does Dennis M. Lanfear currently own?

As insider, Mr. Dennis M. Lanfear owns shares in one company:

Company Title Shares Price per share Total value
Coherus BioSciences, Inc. (CHRS) Chairman, Pres & Chief Executive Officer 731,693 $1.07 $782,912

What does Coherus BioSciences, Inc. do?

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CHRS logo
CHRS
Coherus BioSciences, Inc.
$1.07

Dennis M. Lanfear insider trading

Coherus BioSciences, Inc.

Mr. Dennis M. Lanfear has made 10 insider trades between 2015-2023, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 825,000 units of CHRS stock on 20 Nov 2019. As of 22 Nov 2023 he still owns at least 731,693 units of CHRS stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 258,940 $1.42 $366,918
Option
Common Stock 41,000 $1.42 $58,097
Option
Stock Option (Right to Buy) 299,940 $1.42 $425,015
Sale
Common Stock 223,100 $2.02 $449,770
Sale
Common Stock 31,054 $13.56 $421,216
Option
Stock Option (Right to Buy) 31,054 $13.56 $421,216
Option
Common Stock 31,054 $13.56 $421,216
Option
Common Stock 300,000 $0.42 $125,100
Option
Stock Option (Right to Buy) 300,000 $0.42 $125,100
Option
Common Stock, $0.0001 par value 29,994 $0.01 $240
Option
Stock Option (Right to Buy) 29,994 $0.01 $240
Sale
Common Stock, $0.0001 par value 12,500 $18.56 $231,962
Sale
Common Stock, $0.0001 par value 825,000 $18 $14,850,000
Sale
Common Stock, $0.0001 par value 32,398 $19.49 $631,275
Sale
Common Stock, $0.0001 par value 20,984 $16.26 $341,263
Sale
Common Stock, $0.0001 par value 50 $31.75 $1,588
Sale
Common Stock, $0.0001 par value 4,010 $31.75 $127,322
Sale
Common Stock, $0.0001 par value 2,900 $31.79 $92,200
Sale
Common Stock, $0.0001 par value 400 $31.75 $12,700

Coherus BioSciences key executives

Coherus BioSciences, Inc. executives and other stock owners filed with the SEC: